Beacon Endoscopic Corp. has raised $1.2 million in debt financing from existing investors to fund commercial growth for its bnx™ fine needle aspiration for EUS in the US and abroad, company CEO and President Bill Densel said. Beacon made its regulatory filing to the SEC on July 22. The bnx™ system is “designed to reduce […]
Diagnostics company BG Medicine went public last week. It closed at $8.39 - an increase of 5 percent. The money raised through this public offering will be used to launch its launch of its BGM galectin-3 biomarker test.
Scheduling software is helpful for wellness business owners in numerous ways. They get everything they need to create appointments, reschedule clients and track cancellations in one platform.
The $71.2 million initial public offering should be announced next week. The IPO would help launch the company's BGM Galectin-3 biomarker, which evaluates the risk of a heart attack. The biomarker has won both FDA and European approval.